Stocktoria

Tarsus Pharmaceuticals, Inc. TARS

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-10-16

Tarsus Pharmaceuticals, Inc. statistics & valuation

Market cap$2.7B
P / S6.0×
P / B7.9×
Net margin-14.7%
Return on equity-19.3%
FCF margin-4.9%
Net cash$111.2M
Enterprise value USD$2.6B
Earnings yield EBIT/EV-2.7%
Return on capital-16.6%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Net margin (%)
-24.20% -240.50% -778.90% -63.20% -14.70% 2019202020212022202320242025
Gross margin (%)
2019202020212022202320242025
Operating margin (%)
-21.30% -242.90% -820.50% -65.90% -15.70% 2019202020212022202320242025
Return on equity (%)
-16.20% -8.30% -32.20% -69.00% -51.50% -19.30% 2019202020212022202320242025
Shares outstanding
2.6M 20.3M 20.7M 26.7M 34.2M 38.3M 42.6M 2019202020212022202320242025
Net debt ($)
-$171.3M -$52.2M -$195.1M -$23.0M -$111.2M 2019202020212022202320242025
Share buybacks ($)
2019202020212022202320242025
Return on assets (%)
-8.00% -15.60% -7.70% -27.20% -51.20% -30.70% -11.80% 2019202020212022202320242025
Free cash flow margin (%)
5.50% -191.90% -682.00% -46.20% -4.90% 2019202020212022202320242025
Debt / equity (×)
0.00× 0.10× 0.15× 0.32× 0.21× 2019202020212022202320242025
EPS ($)
-$4.32 -$0.67 -$2.52 -$4.62 -$3.07 -$1.59 2019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Operating margin-15.7%-65.9%-820.5%-242.9%-21.3%——
Net margin-14.7%-63.2%-778.9%-240.5%-24.2%——
FCF margin-4.9%-46.2%-682.0%-191.9%5.5%——
Return on assets-11.8%-30.7%-51.2%-27.2%-7.7%-15.6%-8.0%
Return on equity-19.3%-51.5%-69.0%-32.2%-8.3%-16.2%77.8%
Debt / equity0.21×0.32×0.15×0.10×0.00×——
Current ratio3.854.426.9314.6115.3331.6870.85

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.